| Literature DB >> 34496873 |
Mehrdad Halaji1, Shahrzad Shahidi2, Behrooz Ataei3, Abdolamir Atapour2, Awat Feizi4, Seyed Asghar Havaei5.
Abstract
BACKGROUND: This study aimed to investigate the phylogenetic characterization and virulence traits of uropathogenic Escherichia coli (UPEC) isolated from kidney transplant patients (KTPs) as well as non-KTPs and analyze the clonal distribution of Extended spectrum β-lactamases (ESBLs)-producing UPEC containing blaCTX-M gene.Entities:
Keywords: CTX-M; MLST; Phylogenetic group; Uropathogenic Escherichia coli; Virulence factor
Mesh:
Substances:
Year: 2021 PMID: 34496873 PMCID: PMC8424993 DOI: 10.1186/s12941-021-00470-7
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Distribution of genes encoding virulence factors among KTP and non-KTP isolates
| Function | Virulence factor | Total (n = 111) | KTP (n = 46) | Non-KTP (n = 65) | P-value |
|---|---|---|---|---|---|
| Miscellaneous | 62 (55.9) | 28 (60.9) | 34 (52.3) | 0.37 | |
| Adhesions | 54 (48.6) | 24 (52.2) | 30 (46.2) | 0.53 | |
| 43 (38.7) | 24 (52.2) | 19 (29.2) | 0.01 | ||
| – | – | – | – | ||
| 31 (27.9) | 15 (32.6) | 16 (24.6) | 0.35 | ||
| 17 (15.3) | 6 (13) | 11 (16.9) | 0.57 | ||
| 104 (93.7) | 43 (93.5) | 61 (93.8) | 0.93 | ||
| Toxins | 9 (8.1) | 2 (4.3) | 7 (10.8) | 0.3 | |
| – | – | – | – | ||
| Siderophores | 72 (64.9) | 27 (58.7) | 45 (69.2) | 0.25 | |
| 80 (72.1) | 34 (73.9) | 46 (70.8) | 0.71 | ||
| VF score (mean, median, range) | – | 4.82 ± 1.3, 5(2–9) | 4.97 ± 1.2, 5 (2–8) | 4.72 ± 1.35, 5 (2–9) | 0.31 |
| Phylogenetic groups | B2 | 43 (38.7) | 18 (39.1) | 25 (38.5) | 0.94 |
| D | 21 (18.9) | 10 (21.7) | 11 (16.9) | 0.52 | |
| A | 15 (13.5) | 9 (19.6) | 6 (9.2) | 0.1 | |
| B1 | 10 (9) | 3 (6.5) | 7 (10.8) | 0.51 | |
| C | 6 (5.4) | 0 | 6 (9.2) | 0.03 | |
| E | 5 (4.5) | 1 (2.2) | 4 (6.2) | 0.31 | |
| F | 4 (3.6) | 2 (4.3) | 2 (3.1) | 0.72 | |
| Non | 7 (6.3) | 3 (6.5) | 4 (6.2) | 0.93 |
Values are mean ± SD for continuous and frequency (percentage) for categorical data. P-values resulted from Chi-Squared and ANOVA for categorical and continuous data, respectively
Distribution of VF genes according to phylogroups
| Virulence factor | Phylogenetic group | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| B2 | D | A | B1 | C | E | F | Unknown | ||
| 37(86) | 8 (38.1) | 4 (26.7) | 2 (20) | 1 (16.7) | 1 (20) | 2 (50) | 7 (100) | ≤ 0.05 | |
| 22 (51.2) | 11 (52.4) | 7 (46.7) | 3 (30) | 2 (33.3) | 4 (80) | 2 (50) | 3 (42.9) | > 0.05 | |
| 16 (37.2) | 8 (38.1) | 9 (60) | 6 (60) | – | 2 (40) | 1 (25) | 1 (14.3) | > 0.05 | |
| – | – | – | – | – | – | – | – | > 0.05 | |
| 11 (25.6) | 6 (28.6) | 7 (46.7) | 3 (30) | 1 (16.7) | – | – | 3 (42.9) | > 0.05 | |
| 8 (18.6) | 5 (23.8) | 1 (6.7) | 1 (10) | – | – | – | 2 (28.6) | > 0.05 | |
| 39 (90.7) | 21 (100) | 14 (93.3) | 9 (90) | 6 (100) | 5 (100) | 3 (75) | 7 (100) | > 0.05 | |
| 6 (14) | 2 (9.5) | – | 1 (10) | – | – | – | – | > 0.05 | |
| – | – | – | – | – | – | – | – | > 0.05 | |
| 31 (72.1) | 13 (61.1) | 9 (60) | 5 (50) | 4 (66.7) | 3 (60) | 3 (75) | 4 (57.1) | > 0.05 | |
| VF score (mean, median, range) | 4.95 ± 1.1, 5 (3–8) | 5.5 ± 1.2, 6 (3–7) | 4.4 ± 1.1, 4 (2–7) | 4 ± 1.1, 4 (2–6) | 3.3 ± 1, 4 (2–4) | 5 ± 0.7, 5 (4–6) | 3.7 ± 0.95 | 0.01a | |
Values are mean ± SD for continuous and frequency (percentage) for categorical data. P-values resulted from Chi-Squared and ANOVA for categorical and continuous data, respectively
aDistribution of VF genes in phylogroups B2 was significantly more than phylogroups C
Distribution of the antimicrobial resistance profiles according to phylogroups
| Antibiotics | B2 | D | A | B1 | C | E | F | Unknown | P value |
|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin/clavulanic | 14 (32.6) | 10 (47.7) | 5 (33.4) | 4 (40) | 0 | 0 | 1 (25) | 2 (28.6) | > 0.05 |
| Piperacillin–tazobactam | 4 (9.3) | 3 (14.3) | 1 (6.7) | 3 (30) | 0 | 0 | 1 (25) | 2 (28.6) | > 0.05 |
| Cefoxitin | 10 (23.3) | 4 (19) | 4 (26.7) | 2 (20) | 2 (33.3) | 2 (40) | 1 (25) | 0 | > 0.05 |
| Ceftazidim | 19 (44.2) | 9 (42.9) | 6(40) | 5 (50) | 2 (33.3) | 1 (20) | 2 (50) | 1 (14.3) | > 0.05 |
| Cefixim | 20 (46.5) | 13 (61.9) | 5 (33.3) | 5 (50) | 2 (33.3) | 0 | 1 (50) | 3 (42.9) | > 0.05 |
| Cefepime | 12 (27.9) | 3 (14.3) | 4 (16.6) | 2 (20) | 5 (83.3) | 0 | 2 (50) | 1 (14.3) | > 0.05 |
| Imipenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | > 0.05 |
| Meropenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | > 0.05 |
| Trimethoprim/sulfamethoxazole | 24 (55.8) | 13 (61.9) | 9 (60) | 8 (80) | 4 (66.7) | 4 (80) | 3 (75) | 5 (71.4) | > 0.05 |
| Ciprofloxacin | 22 (51.2) | 8(38.1) | 7 (46.7) | 6 (60) | 1 (16.7) | 1 (20) | 3 (75) | 3 (42.9) | > 0.05 |
| Ofloxacin | 24 (55.8) | 9 (42.9) | 6 (40) | 6 (60) | 2 (33.3) | 3 (60) | 3 (75) | 3 (42.9) | > 0.05 |
| Nalidixic acid | 32 (74.4) | 15 (71.4) | 10 (66.7) | 8 (80) | 3 (50) | 3(60) | 4 (100) | 3 (42.9) | > 0.05 |
| Norfloxacin | 21 (48.8) | 8 (38.1) | 7 (46.7) | 6 (60) | 1 (16.7) | 1 (20) | 2 (50) | 3 (42.9) | > 0.05 |
| Nitrofurantoin | 3 (7) | 7 (33.3) | 4 (26.7) | 2 (20) | 1 (16.7) | 2 (40) | 1 (25) | 0 | ≤ 0.05 |
| Gentamicin | 12 (27.9) | (14.3) 3 | 4 (26.7) | 3 (30) | 1 (16.7) | 3 (60) | 0 | 0 | > 0.05 |
| Amikacin | 0 | 0 | 0 | 1 (10) | 0 | 0 | 0 | 1 (14.3) | > 0.05 |
| Resistance score (mean, median, range) | 4.88, 5, (0–11) | 4.9±, 5, (0–11) | 4.33, 3, (0–11) | 5.5, 6, (0–11) | 2.83, 2, (0–8) | 4, 4, (0–8) | 5.5, 5, (0–10) | 3.7, 3, (0–9) | > 0.05 |
| ESBL | 17(39.5) | 7 (33.3) | 4 (26.6) | 2 (20) | 2 (33.3) | 1 (20) | 2 (50) | – | > 0.05 |
| 25 (58.1) | 11 (52.4) | 8 (53.3) | 3 (30) | 3 (50) | 2 (40) | 1 (25) | 6 (85.7) | > 0.05 | |
| 20 (46.5) | 12 (57.1) | 7 (46.7) | 2 (20) | 2 (33.3) | 2 (40) | 2 (50) | 3 (42.9) | > 0.05 | |
| 1 (2.3) | 2 (9.5) | 1 (6.7) | 1 (10) | – | – | – | 1 (14.3) | > 0.05 |
Characteristics of the 29 bla -producing UPEC
| Strain | Type of patients | Antibiotic resistance pattern | ESBL genes | ESBL | Virulence profile | Phylogenetic groups | ST | CC |
|---|---|---|---|---|---|---|---|---|
| 103 | KTP | TS, NA, Nor, OFX, CIP, CAZ, CFM, AUG | bla | + | D | 90 | 23 | |
| 120 | KTP | TS, NA, Nor, FOX, OFX, GM, FEP CIP, CAZ, CFM, AUG | bla | + | D | 405 | 405 | |
| 122 | KTP | TS, TZP, CAZ, CFM, FM | bla | + | D | 69 | 69 | |
| 9 | KTP | TS, NA, Nor, FOX, OFX, GM, FEP CIP, CAZ | bla | + | B2 | 131 | 131 | |
| 127 | KTP | TS, NA, Nor, FOX, OFX, CIPFEP, TZP, CAZ, CFM, AUG | bla | + | B2 | 8503 | 131 | |
| 147 | KTP | TS, NA, Nor, OFX, CIP, CAZ, CFM, AUG | bla | + | B2 | 2114 | 648 | |
| 112 | KTP | TS, NA, Nor, FOX OFX, CIP, GM CAZ CFM, | bla | + | B2 | 1193 | 14 | |
| 124 | KTP | TS, NA, Nor, FOX OFX, CIP, GM CAZ, CFM | bla | + | B2 | 1193 | 14 | |
| 138 | KTP | TS, NA, FEP, CAZ, CFM | bla | + | D | 38 | 38 | |
| 72 | KTP | TS, NA, Nor, OFX, CIP, CAZ, CFM | bla | + | F | 38 | 38 | |
| 139 | KTP | TS, NA, Nor, OFX, CIP, GM, FEP, TZP, CFM, FM | bla | + | B1 | 617 | 10 | |
| 121 | KTP | TS, NA, Nor, FOX, OFX, GM, CIP, CAZ CFM | bla | + | A | 744 | 10 | |
| 101 | KTP | NA, NOR, OFX, CIP, FEP, AUG | bla | + | B2 | 838 | 131 | |
| 128 | KTP | TS, NA, Nor, OFX, GM, CIP, CAZ | bla | + | A | 4988 | 10 | |
| 110 | KTP | TS, NA, NOR, OFX, GM, CIP, FEP, TZP, CAZ, CFM | bla | + | B2 | 4516 | ||
| 146 | KTP | TS, NA, Nor, OFX, CIP, CAZ | bla | + | B2 | 131 | 131 | |
| 148 | KTP | TS, NA, Nor, OFX, GM, CIP, CAZ, FEP | bla | + | B2 | 131 | 131 | |
| 129 | KTP | TS, NA, Nor, FOX, OFX, CIP, TZP, FEP, CAZCFM, AUG | bla | + | A | 131 | 131 | |
| 137 | KTP | NA, GM, TZP, CAZ, CFM, FM | bla | + | D | 127 | 127 | |
| 57 | Non-KTP | NA, Nor, Fox, OFX, GM, CIP, CAZ, FM | bla | + | B2 | 8503 | 131 | |
| 89 | Non-KTP | TS, NA, NOR, OFX, CIP, CAZ, CTX, CFM, AUG | bla | + | B2 | 131 | 131 | |
| 61 | Non-KTP | TS, NA, OFX, CAZ, CFM | bla | + | A | 2115 | ||
| 78 | Non-KTP | NA, Nor, Fox, OFX, GM, CIP, CAZ, CFM, AUG | bla | + | B2 | 1193 | 14 | |
| 59 | Non-KTP | TS, NA, Nor, Fox, OFX, GM, FEP CIP, CAZ, CFM | bla | + | B2 | 131 | 131 | |
| 80 | Non-KTP | TS, NA, TZP, CAZ, CAZ, CFM, AUG | bla | + | B2 | 636 | – | |
| 87 | Non-KTP | TS, OFX, GM, CAZ | bla | + | E | – | – | |
| 56 | Non-KTP | NA, Nor, OFX, CIP, CAZ, CFM | bla | + | B2 | 648 | 648 | |
| 33 | Non-KTP | TS, CAZ, CFM | bla | + | B2 | 167 | 10 | |
| 79 | Non-KTP | TS, NA, Nor, OFX, GM, FEP CIP, CAZ, CFM | bla | + | B2 | 131 | 131 |
Fig. 1Phylogenetic tree of MLST for the bla positive strains; clonal complexes are shown with haloes. The colors of the circles correspond to the type of patients (Red: transplanted patients; Blue: Control group)